List of Excipients in Branded Drug DURYSTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	DURYSTA	bimatoprost	0023-9652	DL-LACTIDE AND GLYCOLIDE
Allergan Inc	DURYSTA	bimatoprost	0023-9652	POLYETHYLENE GLYCOL
Allergan Inc	DURYSTA	bimatoprost	0023-9652	POLYLACTIDE

DURYSTA Excipient Strategy and Commercial Opportunities in Bimatoprost Ocular Implants

Last updated: August 2, 2026

DURYSTA is a biodegradable intracameral implant that delivers 10 micrograms of bimatoprost for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its commercial value depends less on the active pharmaceutical ingredient, which is widely available, than on controlled polymer degradation, implant manufacturability, intracameral delivery, sterilization, and corneal safety. The strongest excipient opportunities are in biodegradable polymer systems, implant processing, release-control technologies, and device-compatible manufacturing rather than conventional ophthalmic excipients.

What is DURYSTA and how does its formulation work?

DURYSTA contains bimatoprost in a biodegradable polymer matrix. The implant is placed directly into the anterior chamber through a single-use applicator. The matrix gradually degrades and releases bimatoprost over an extended period, reducing the need for daily topical administration (FDA, 2024a).

Attribute	DURYSTA profile
Active ingredient	Bimatoprost
Dose	10 micrograms per implant
Route	Intracameral administration
Indication	Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension
Dosage form	Biodegradable ocular implant
Administration	Administered by an ophthalmic professional
Primary release mechanism	Diffusion and polymer degradation
Commercial sponsor	AbbVie, following its acquisition of Allergan
FDA pathway	New drug application, NDA 211911
Key formulation risk	Corneal endothelial cell loss and implant-related ocular complications

The implant approach changes the excipient function. The polymer is not simply a carrier or viscosity modifier. It determines drug loading, implant strength, placement behavior, degradation products, residence time, dose uniformity, and ocular tolerability.

What excipients are used in DURYSTA?

The principal formulation excipient is a biodegradable lactide-based polymer. Public FDA labeling describes the implant as bimatoprost contained in a biodegradable polymer matrix. The commercial formulation does not rely on the typical excipients found in eye drops, such as benzalkonium chloride, polysorbate, borate buffers, or viscosity agents (FDA, 2024a).

Biodegradable polymer matrix

The matrix must satisfy several requirements simultaneously:

• Maintain mechanical integrity during manufacture and implantation.
• Release bimatoprost at a controlled rate.
• Degrade into tolerable products in the ocular environment.
• Avoid excessive swelling, migration, or fragmentation.
• Maintain dose uniformity at the 10-microgram scale.
• Remain compatible with sterilization and packaging.
• Avoid adverse effects on the corneal endothelium and anterior chamber.

A lactide-based polymer is commercially attractive because its degradation chemistry is established in parenteral drug delivery and implantable medical devices. The main variables are molecular weight, polymer end-group chemistry, crystallinity, residual monomer, particle size, and implant geometry.

Magnesium stearate and process aids

Public product information identifies polymer-based implant materials and may include process-related components depending on the specific manufacturing presentation and regulatory disclosure. Magnesium stearate and similar lubricants can be relevant to implant processing, but they should not be treated as interchangeable with ordinary tablet-grade material. For an intracameral product, lubricant residue, particulate burden, extractables, and local tolerability require separate qualification.

The commercial opportunity is therefore concentrated in ophthalmic-grade or implant-grade excipient control. A supplier with low-metal, low-particulate, low-bioburden material and robust lot-to-lot polymer characterization has more value than a low-cost commodity supplier.

What excipient properties are most important for DURYSTA development?

Molecular-weight control

Polymer molecular weight directly affects degradation rate, melt or solvent processing, mechanical strength, and release duration. A narrow molecular-weight distribution can improve batch reproducibility. Excessively low molecular weight may accelerate degradation and produce an early release spike. Excessively high molecular weight may prolong release and complicate processing.

Residual monomer and solvent limits

Lactide-based polymers can contain residual monomer, oligomers, solvents, catalysts, and processing impurities. In an intracameral implant, these impurities have direct exposure to sensitive ocular tissues. Supplier qualification should include:

• Residual lactide and oligomer profile.
• Residual solvent testing.
• Heavy-metal and catalyst residues.
• Bioburden and endotoxin controls.
• Extractables and leachables from packaging.
• Stability of the polymer during storage.

Degradation-product management

Polymer degradation can generate acidic products. Local pH shifts may affect ocular tolerability, drug stability, and corneal endothelial health. Formulation developers should evaluate degradation-product concentration within the implant microenvironment, not only bulk aqueous release.

Mechanical behavior

The implant must be rigid enough for placement but not so hard that it damages ocular tissues or complicates injector performance. Dimensional stability is important because small variations in implant volume or geometry can materially affect dose release.

Sterilization compatibility

Sterilization can change polymer molecular weight, drug potency, color, brittleness, and release kinetics. Gamma irradiation, electron-beam processing, ethylene oxide, and aseptic manufacturing create different regulatory and technical profiles. A change in sterilization method can become a formulation change requiring comparability data.

What formulation patents protect DURYSTA-type implants?

Protection for a biodegradable bimatoprost implant typically extends across several patent categories:

1. Composition-of-matter claims covering bimatoprost in a biodegradable polymer matrix.
2. Implant geometry and dose-loading claims.
3. Controlled-release profiles.
4. Intracameral administration methods.
5. Applicator and delivery-device configurations.
6. Manufacturing methods for forming and loading the implant.
7. Use claims for glaucoma or ocular hypertension.
8. Polymer composition and degradation-rate limitations.

The active ingredient itself does not provide a strong exclusivity barrier because bimatoprost is an established prostaglandin analogue. The more valuable claims are likely to concern the combination of drug, biodegradable matrix, implant dimensions, release kinetics, and delivery system.

The FDA Orange Book should be reviewed for current patent listings associated with NDA 211911. Patent status can differ by jurisdiction, patent family, terminal disclaimer, pediatric extension, and regulatory exclusivity. A freedom-to-operate analysis should separate claims directed to the implant from claims directed to the injector and method of administration (FDA, 2024b; USPTO, 2024).

When does DURYSTA lose regulatory and patent exclusivity?

DURYSTA received FDA approval on February 4, 2020. The standard new-chemical-entity exclusivity period generally does not apply in the same manner as a product containing a new active ingredient because bimatoprost had previously been approved. The commercial protection therefore depends primarily on listed patents, formulation claims, device claims, method-of-use claims, and any applicable regulatory exclusivity.

Exclusivity element	Strategic significance
FDA approval	Established the product-specific safety and efficacy profile
Active ingredient	Limited protection because bimatoprost was previously approved
Formulation patents	Potentially strong if claims cover polymer, dose, geometry, and release
Device patents	Important for injector design and administration method
Method-of-use patents	May limit labeled intracameral use
Orange Book listings	Determine the patent certifications required for ANDA applicants
Pediatric exclusivity	Must be confirmed from the current regulatory record
Patent term adjustment	Can extend individual patent expiration dates
Patent term extension	May apply only to an eligible patent and cannot be assumed across the estate

A precise generic-entry date requires a current Orange Book record and review of each patent family. An ANDA applicant may challenge listed patents through a Paragraph IV certification, wait for patent expiry, or seek a non-infringing product design.

What generic entry risks exist for DURYSTA?

A conventional ANDA is more difficult for DURYSTA than for a topical bimatoprost solution. The applicant must demonstrate pharmaceutical equivalence and bioequivalence for a complex implant administered directly into the eye. The critical comparators include:

• Bimatoprost dose per implant.
• Implant dimensions and mass.
• Polymer composition.
• Drug distribution within the matrix.
• In vitro release profile.
• Degradation kinetics.
• Sterility assurance.
• Injector performance.
• Implant placement and retention.
• Ocular exposure and safety.

An applicant may pursue one of three broad strategies:

1. Same-polymer implant

This approach may provide the most direct regulatory comparison but creates the greatest risk of infringement. It may require a Paragraph IV challenge against composition, process, release, and device patents.

2. Alternative biodegradable polymer

A different polymer or copolymer could reduce patent exposure. The regulatory burden may increase because changes in polymer chemistry can alter degradation products, tissue exposure, release kinetics, and clinical performance.

3. 505(b)(2) controlled-release product

A 505(b)(2) applicant could rely partly on DURYSTA data while developing a distinct implant, formulation, dose, or delivery system. This route may be commercially attractive for a lower-frequency or safer-release product, but it would not automatically avoid patent litigation.

The main generic barrier is not raw-material access. It is the need to reproduce a clinically acceptable intracameral release system while controlling ocular safety.

What excipient opportunities exist for competing products?

Alternative biodegradable polymers

Potential development areas include:

• Poly(D,L-lactide) with controlled molecular weight.
• Lactide-glycolide copolymers with adjusted degradation rates.
• Polymer blends that reduce burst release.
• End-capped polymers with slower hydrolysis.
• Low-acid-generation matrices.
• Surface-modified implants that reduce tissue interaction.

A competitor must avoid treating PLGA as an automatic substitute for a lactide-based matrix. Glycolide content, polymer crystallinity, water uptake, and degradation products can produce materially different ocular behavior.

Drug-polymer processing

Commercial opportunities include solvent-free extrusion, precision molding, micro-injection molding, hot-melt processing, and solvent casting. Process control is especially valuable because the dose is small and minor changes in implant dimensions can affect exposure.

Coatings and release-control layers

A thin biodegradable coating could reduce initial burst release or alter residence time. Coatings also create new risks involving delamination, particulates, incomplete degradation, and ophthalmic tolerability.

Excipient and polymer supply

A qualified supplier can differentiate through:

• Custom molecular-weight specifications.
• Low-endotoxin manufacturing.
• Regulatory documentation.
• Retained samples and traceability.
• Multi-site supply.
• Stability data.
• Compendial and non-compendial impurity methods.
• Change-control commitments.

For a product with a single implant and single-use applicator, supply interruption can affect both drug and device production. Dual sourcing is commercially valuable but difficult if the alternative polymer does not reproduce release performance.

How does DURYSTA compare with topical bimatoprost products?

Factor	DURYSTA	Topical bimatoprost
Administration	Intracameral procedure	Daily eye drops
Adherence burden	Lower after administration	Higher because of daily dosing
Excipient system	Biodegradable implant matrix	Aqueous solution with preservatives and buffers
Manufacturing complexity	High	Moderate
Device dependence	High	Low to moderate
Patent barrier	Formulation, device, and use claims	Formulation and use claims
Main safety concern	Corneal endothelial cell loss and procedure-related risks	Ocular surface effects and prostaglandin-associated changes
Generic substitution	Technically difficult	More accessible
Commercial positioning	Long-acting, procedure-based therapy	Lower-cost chronic topical therapy

DURYSTA can command clinical value where adherence is poor, but physician administration, procedure reimbursement, repeat-treatment limitations, and corneal safety can restrict uptake.

What FDA regulatory issues affect DURYSTA commercial opportunities?

FDA labeling states that repeat administration has not been established as a routine strategy and identifies important ocular risks, including corneal endothelial cell loss. The product label also contains administration restrictions and warnings relevant to patient selection (FDA, 2024a).

These restrictions affect excipient strategy. A polymer that extends release duration may be commercially attractive, but longer ocular residence can increase cumulative exposure to degradation products or complicate removal if adverse effects occur. A safer product may therefore require:

• Lower burst release.
• More predictable degradation.
• Reduced implant migration.
• Lower particulate generation.
• Improved injector placement.
• A resorbable matrix with a defined clearance profile.
• A dose that supports repeat administration without excessive endothelial risk.

Which companies are positioned to challenge or extend the DURYSTA market?

The relevant competitive groups are:

• Generic pharmaceutical companies with ophthalmic ANDA capabilities.
• Specialty ophthalmology companies developing sustained-release implants.
• Drug-delivery companies with biodegradable microparticle platforms.
• Medical-device manufacturers with intracameral delivery systems.
• Polymer suppliers with implant-grade lactide materials.
• Contract development and manufacturing organizations with sterile micro-implant capabilities.

The most credible challengers will combine ophthalmic clinical development with device engineering and polymer science. A generic drug company without implant manufacturing capability may need a partnership with a device or specialty-delivery company.

How strong is the DURYSTA patent estate?

The estate is likely stronger against simple copy products than against redesigned delivery systems. Product claims covering a specific bimatoprost implant, polymer matrix, geometry, and release profile can create a meaningful barrier. Device claims can add another layer of risk. Method-of-use claims may be narrower if they depend on the approved indication or a specific dosing schedule.

The estate is weaker where a competitor can:

• Use a different polymer architecture.
• Change implant geometry.
• Alter dose strength.
• Develop a different release mechanism.
• Use a separate injector.
• Pursue a 505(b)(2) pathway with a distinct clinical and formulation profile.

Patent strength should be assessed claim by claim. A large number of patents does not necessarily indicate broad protection if most claims are narrow, expired, terminally disclaimed, or vulnerable to design-around.

What licensing opportunities exist around DURYSTA-type technology?

Commercial licensing opportunities include:

1. Polymer supply agreements with formulation-specific specifications.
2. Co-development of alternative bimatoprost implants.
3. Regional rights for ophthalmic sustained-release products.
4. Device licensing for intracameral applicators.
5. Manufacturing licenses for implant molding and sterilization.
6. 505(b)(2) partnerships combining an established active ingredient with a new delivery system.
7. Platform licenses for other prostaglandin analogues, including travoprost or latanoprost.

The highest-value deals are likely to involve bundled rights covering polymer formulation, implant manufacture, sterile filling or packaging, and the delivery device. Licensing only the active ingredient creates little differentiation.

Key Takeaways

• DURYSTA’s central excipient is its biodegradable polymer matrix, not a conventional ophthalmic solution excipient.
• Commercial differentiation depends on release control, ocular tolerability, sterilization, and injector performance.
• The strongest IP barriers are likely to involve implant composition, geometry, release profile, manufacturing, device design, and intracameral use.
• Bimatoprost itself offers limited exclusivity because it is an established active ingredient.
• Generic entry is more difficult than for topical bimatoprost because the product combines drug, polymer, sterile implant, and delivery device.
• Alternative polymers and lower-burst-release systems provide the clearest formulation opportunities.
• A 505(b)(2) strategy may offer a practical route for a differentiated long-acting bimatoprost implant.
• Supplier value is concentrated in implant-grade polymer consistency, impurity control, regulatory documentation, and dual-source readiness.
• Corneal endothelial safety is the primary constraint on extending residence time or repeat administration.
• The current Orange Book and patent-family record should control any launch, licensing, or Paragraph IV assessment.

FAQs

Can PLGA replace the polymer used in DURYSTA?

PLGA may be technically feasible, but it is not a direct substitute. Its glycolide content, water uptake, degradation rate, acidity, and release profile must be optimized for intracameral use and supported by comparative safety and performance data.

Is DURYSTA eligible for a conventional generic application?

A conventional ANDA may be possible, but the applicant must address complex implant equivalence, release testing, sterility, injector performance, and ocular safety. A 505(b)(2) pathway may be more practical for a materially different implant.

What is the most valuable excipient claim in a DURYSTA competitor?

Claims covering the polymer composition combined with implant geometry, bimatoprost loading, and a defined release profile are likely to have greater commercial value than claims covering a generic biodegradable polymer alone.

Can a longer-lasting DURYSTA formulation command a premium?

Potentially, but longer duration must be balanced against endothelial safety, repeat-treatment limitations, degradation-product exposure, and physician acceptance. A longer-lasting implant with a less favorable safety profile may have limited commercial value.

Are biosimilar rules relevant to DURYSTA?

No. DURYSTA contains a chemically synthesized small-molecule active ingredient and is regulated as a drug-device combination involving a small-molecule drug product, not as a biologic subject to the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024a). DURYSTA (bimatoprost implant) prescribing information. AbbVie Inc.

2. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2020). FDA approves first implant to treat glaucoma. https://www.fda.gov/

4. U.S. Patent and Trademark Office. (2024). Patent Center and patent search resources. https://www.uspto.gov/

5. European Medicines Agency. (2024). Guideline on quality of ophthalmic preparations. https://www.ema.europa.eu/